Abstract
Purpose of Review
Since the discovery of imatinib, an oral breakpoint cluster region—Abelson murine leukemia tyrosine kinase inhibitor, chronic myelogenous leukemia transformed from a hematologic malignancy primarily treated with intravenous chemotherapy to a disease almost solely managed with oral agents. While certainly there are benefits to taking a medication at home, this change in treatment modality also came with unique challenges, including patient adherence, medication acquisition and cost, and toxicity management.
Recent Findings
Pharmacists are uniquely equipped to assist with educating patients, safe prescribing, and access to medications. Several studies have described the benefits of an integrated oral anticancer medication management program in the ambulatory setting, including improvements in patient adherence, side effect management, patient comprehension, and drug-interaction detection. Pharmacists are also specially trained to assist with medication dose adjustments, relative lab monitoring, and co-pay assistance.
Summary
Here, we describe the multidisciplinary workflows established to manage oral therapies in chronic myelogenous leukemia patients in a malignant hematology clinic at a large academic medical center. By using the unique talents of the clinic pharmacist, clinic nurse, and specialty retail pharmacy group, patients can be triaged to help ensure the correct skill set is used to optimally care for patients. An acuity-based monitoring structure can improve the ability to reach and safely monitor a large volume of patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
O’Brien SG, Fo Guilhot, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994–1004. https://doi.org/10.1056/NEJMoa022457.
Ganesan P, Sagar TG, Dubashi B, Rajendranath R, Kannan K, Cyriac S, et al. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol. 2011;86(6):471–4. https://doi.org/10.1002/ajh.22019.
Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381–8. https://doi.org/10.1200/JCO.2009.26.3087.
Noens L, van Lierde MA, De Bock R, Verhoef G, Zachee P, Berneman Z, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113(22):5401–11. https://doi.org/10.1182/blood-2008-12-196543.
McCue DA, Lohr LK, Pick AM. Improving adherence to oral cancer therapy in clinical practice. Pharmacotherapy. 2014;34(5):481–94. https://doi.org/10.1002/phar.1399.
Lam MS, Cheung N. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia. J Oncol Pharm Pract. 2016;22(6):741–8. https://doi.org/10.1177/1078155215608523.
••Muluneh B, Schneider M, Faso A, Amerine L, Daniels R, Crisp B, et al. Improved adherence rates and clinical outcomes of an integrated, closed-loop, pharmacist-led oral chemotherapy management program. J Oncol Pract. 2018;14(6):e324–34. https://doi.org/10.1200/JOP.17.00039Outlines the major impact a pharmacist-led oral chemotherapy management program can have on improving patient knowledge, adherence, and possibly CML response rates.
••Morgan KP, Muluneh B, Deal AM, Amerine LB. Impact of an integrated oral chemotherapy program on patient adherence. J Oncol Pharm Pract. 2018;24(5):332–6. https://doi.org/10.1177/1078155217703792Reveals how an integrated, pharmacist-led oral chemotherapy program , in collaboration with their internal specialty pharmacy colleagues, had high medication possession ratios for patients that filled at the institution’s specialty pharmacy.
Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, et al. Long-term follow-up of the French Stop Imatinib (STIM1) Study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35(3):298–305. https://doi.org/10.1200/JCO.2016.68.2914.
Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, et al. Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial. JAMA Oncol. 2020. https://doi.org/10.1001/jamaoncol.2020.5774.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Angela Canadeo, Mary Fournogerakis, and Felicia Zook declare no potential conflicts of interest.
Human and Animal Rights and Informed Consent
This article contains no studies with human or animal subjects performed by any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Chronic Myeloid Leukemias
Rights and permissions
About this article
Cite this article
Canadeo, A., Fournogerakis, M. & Zook, F. A Multi-disciplinary Approach to Managing Chronic Myelogenous Leukemia Patients on Oral Anticancer Therapy at a Large Academic Medical Center. Curr Hematol Malig Rep 16, 509–516 (2021). https://doi.org/10.1007/s11899-021-00659-9
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11899-021-00659-9